The Anti-Dopamine Receptor D2L (DRD2L) test measures autoantibodies directed against the D2 “long isoform” dopamine receptor, one of the most important dopamine receptors in the brain. D2L receptors are heavily involved in motor control, reward and motivation circuits, emotional regulation, executive function, and the modulation of neurotransmitter release.
When the immune system produces antibodies against D2L receptors, it may interfere with normal dopamine signaling. This process has been associated with immune-mediated neuroinflammation, particularly in children and adolescents experiencing sudden or severe neuropsychiatric symptoms. Elevated DRD2L titers have been observed in conditions such as PANS (Pediatric Acute-Onset Neuropsychiatric Syndrome), PANDAS, Sydenham chorea, and other post-infectious or autoimmune neurological disorders.
The D2L receptor is especially significant because abnormalities in D2 signaling have been linked to tics, compulsions, emotional lability, agitation, mood instability, and movement disorders. When antibodies bind to these receptors, they may disrupt dopamine’s ability to regulate neural pathways, contributing to these symptoms.
This marker is part of the Autoimmune Brain Panel™, a specialized neuro-immune test designed to assess whether autoimmune activity may be affecting neuronal structures. While DRD2L antibodies alone do not diagnose any condition, they provide important supporting evidence when evaluated alongside symptoms, infection history, other neuronal autoantibodies (DRD1, anti-tubulin, anti-lysoganglioside GM1), and CaMKII activation levels.
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.